Cerus Corp
NASDAQ:CERS
Intrinsic Value
Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. [ Read More ]
The intrinsic value of one CERS stock under the Base Case scenario is 2.42 USD. Compared to the current market price of 1.67 USD, Cerus Corp is Undervalued by 31%.
Valuation Backtest
Cerus Corp
Run backtest to discover the historical profit from buying and selling CERS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Cerus Corp
Current Assets | 144.4m |
Cash & Short-Term Investments | 65.9m |
Receivables | 35.5m |
Other Current Assets | 43.1m |
Non-Current Assets | 53.3m |
PP&E | 19.4m |
Intangibles | 1.3m |
Other Non-Current Assets | 32.6m |
Current Liabilities | 67.5m |
Accounts Payable | 23.8m |
Accrued Liabilities | 21.7m |
Other Current Liabilities | 22m |
Non-Current Liabilities | 77.6m |
Long-Term Debt | 59.8m |
Other Non-Current Liabilities | 17.8m |
Earnings Waterfall
Cerus Corp
Revenue
|
186.8m
USD
|
Cost of Revenue
|
-70m
USD
|
Gross Profit
|
116.8m
USD
|
Operating Expenses
|
-143.2m
USD
|
Operating Income
|
-26.3m
USD
|
Other Expenses
|
-11.2m
USD
|
Net Income
|
-37.5m
USD
|
Free Cash Flow Analysis
Cerus Corp
What is Free Cash Flow?
CERS Profitability Score
Profitability Due Diligence
Cerus Corp's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Cerus Corp's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
CERS Solvency Score
Solvency Due Diligence
Cerus Corp's solvency score is 33/100. The higher the solvency score, the more solvent the company is.
Score
Cerus Corp's solvency score is 33/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CERS Price Targets Summary
Cerus Corp
According to Wall Street analysts, the average 1-year price target for CERS is 4.39 USD with a low forecast of 2.53 USD and a high forecast of 6.3 USD.
Ownership
CERS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
CERS Price
Cerus Corp
Average Annual Return | -2.14% |
Standard Deviation of Annual Returns | 47.71% |
Max Drawdown | -85% |
Market Capitalization | 302.7m USD |
Shares Outstanding | 181 283 008 |
Percentage of Shares Shorted | 3.34% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The company is headquartered in Concord, California and currently employs 294 full-time employees. The company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, which is based on its technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives, such as plasma, platelets, red blood cells. Its product or product candidates under development includes INTERCEPT Blood System-Platelets, INTERCEPT Blood System-Plasma, INTERCEPT Blood System-Red Blood Cells and INTERCEPT Blood System-Cryoprecipitation. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products.
Contact
IPO
Employees
Officers
The intrinsic value of one CERS stock under the Base Case scenario is 2.42 USD.
Compared to the current market price of 1.67 USD, Cerus Corp is Undervalued by 31%.